The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12839953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone Deacetylase Inhibitors in Cancer Therapy

  2003cited by this paper
• Correlation of chronic hepatitis B and C with diabetes mellitus

  2002cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

  2002cited by this paper
• Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence

  2002cited by this paper
• MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.

  2002cited by this paper
• Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.

  2002cited by this paper
• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

  2002cited by this paper
• Histone deacetylase inhibitors in cancer treatment.

  2002cited by this paper
• Histone deacetylase inhibitors in cancer treatment.

  2002cited by this paper
• Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells*

  2002cited by this paper
• The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.

  2002cited by this paper
• The Histone Deacetylase Inhibitor Sodium Butyrate Interacts Synergistically with Phorbol Myristate Acetate (PMA) to Induce Mitochondrial Damage and Apoptosis in Human Myeloid Leukemia Cells through a Tumor Necrosis Factor-α-Mediated Process

  2002cited by this paper
• The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells.

  2002cited by this paper
• Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

  2002cited by this paper
• Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).

  2001cited by this paper
• Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.

  2001cited by this paper
• p21 gene regulation during enterocyte differentiation.

  2001cited by this paper
• MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.

  2001cited by this paper
• Histone deacetylase inhibitors induce caspase‐dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)

  2001cited by this paper
• Histone deacetylase inhibitors as new cancer drugs

  2001cited by this paper
• Constitutive hyperexpression of p21(WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas.

  2001cited by this paper
• Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

  2001cited by this paper
• The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

  2001cited by this paper
• Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

  2000influential reference
• Caspase 3-mediated Cleavage of p21 WAF1/CIP1 Associated with the Cyclin A-Cyclin-dependent Kinase 2 Complex Is a Prerequisite for Apoptosis in SK-HEP-1 Cells*

  2000cited by this paper
• Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

  2000cited by this paper
• [Mitochondria and apoptosis].

  2000cited by this paper
• Potentiation of 1-β- d-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) ∗ ∗ Portions of this work have been reported in preliminary form at the Meeting for the American Ass

  2000cited by this paper
• Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.

  2000cited by this paper
• The Pezcoller lecture: cancer cell cycles revisited.

  2000cited by this paper
• Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).

  2000cited by this paper
• Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.

  1999cited by this paper
• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

  1999cited by this paper
• Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?

  1999cited by this paper
• Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.

  1999cited by this paper
• A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

  1999cited by this paper
• Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

  1999cited by this paper
• Caspase-3-dependent Cleavage of Bcl-2 Promotes Release of Cytochrome c *

  1999cited by this paper
• Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure–function analysis

  1999cited by this paper
• Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21

  1999cited by this paper
• BCL-2 family members and the mitochondria in apoptosis.

  1999cited by this paper
• Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.

  1999cited by this paper
• Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.

  1999cited by this paper
• Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

  1999cited by this paper
• p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage

  1998cited by this paper
• Mitochondria and apoptosis.

  1998cited by this paper
• Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals.

  1998cited by this paper
• Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis.

  1998cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells.

  1998cited by this paper
• Enhanced Oxidative Stress and Altered Antioxidants in Brains of Bcl‐2‐Deficient Mice

  1998cited by this paper
• p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells

  1998cited by this paper
• Cleavage of CDK Inhibitor p21Cip1/Waf1 by Caspases Is an Early Event during DNA Damage-induced Apoptosis*

  1998cited by this paper
• The mitochondrial death/life regulator in apoptosis and necrosis.

  1998cited by this paper
• Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo

  1998cited by this paper
• Conversion of Bcl-2 to a Bax-like death effector by caspases.

  1997cited by this paper
• Direct evidence for antioxidant effect of Bcl-2 in PC12 rat pheochromocytoma cells.

  1997cited by this paper
• Target Protease Specificity of the Viral Serpin CrmA

  1997cited by this paper
• Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.

  1997cited by this paper
• Direct inhibition of the expression of cyclin D1 gene by sodium butyrate.

  1996cited by this paper
• [Oxidative stress and apoptosis].

  1996cited by this paper
• Mitochondrial control of nuclear apoptosis

  1996cited by this paper
• The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

  1996cited by this paper
• Induction of Apoptosis and Potentiation of Ceramide-mediated Cytotoxicity by Sphingoid Bases in Human Myeloid Leukemia Cells (*)

  1996cited by this paper
• Tumor necrosis factors: developments during the last decade.

  1996cited by this paper
• Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death

  1995cited by this paper
• Progression of the myeloid differentiation program is dominant to transforming growth factor-beta 1-induced apoptosis in M1 myeloid leukemic cells.

  1994cited by this paper
• Bcl-2 functions in an antioxidant pathway to prevent apoptosis.

  1993cited by this paper
• Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1

  1988cited by this paper

• Effect of Native Hemp Seed Oil Enriched with Cannabidiol on Epigenetic Stability and Oxidative Stress Status of Colon Cancer Cells

  2025cites this paper
• Histone Deacetylase Inhibitors Promote the Anticancer Activity of Cisplatin: Mechanisms and Potential

  2025cites this paper
• A comprehensive review on azole-based hydroxamic acid analogs as histone deacetylases (HDACs) inhibitors.

  2025cites this paper
• HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma

  2025cites this paper
• Highly quantitative measurement of differential protein-genome binding with PerCell chromatin sequencing

  2025cites this paper
• Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections

  2025cites this paper
• Epigenetic regulation of the tumor microenvironment in lung cancer: mechanism insights and therapeutic prospects

  2025cites this paper
• A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

  2025cites this paper
• Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation

  2024cites this paper
• HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer.

  2024cites this paper
• Highly quantitative measurement of differential protein-genome binding with PerCell chromatin sequencing

  2024cites this paper
• Pan-cancer exploration of PNO1: A prospective prognostic biomarker with ties to immune infiltration

  2024cites this paper
• Absence of HDAC3 by Matrix Stiffness Promotes Chromatin Remodeling and Fibroblast Activation in Idiopathic Pulmonary Fibrosis

  2023cites this paper
• Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

  2023cites this paper
• Biological Effects of HDAC Inhibitors Vary with Zinc Binding Group: Differential Effects on Zinc Bioavailability, ROS Production, and R175H p53 Mutant Protein Reactivation

  2023cites this paper
• Ligand-based active targeting strategies for cancer theranostics

  2023cites this paper
• The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis

  2023cites this paper
• An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review

  2023cites this paper
• Effects of HDAC inhibitors on neuroblastoma SH-SY5Y cell differentiation into mature neurons via the Wnt signaling pathway

  2023cites this paper
• Rhizoaspergillin A and Rhizoaspergillinol A, including a Unique Orsellinic Acid–Ribose–Pyridazinone-N-Oxide Hybrid, from the Mangrove Endophytic Fungus Aspergillus sp. A1E3

  2023cites this paper
• Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention

  2022cites this paper
• Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.

  2022cites this paper
• CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia

  2022cites this paper
• Histone Modification on Parathyroid Tumors: A Review of Epigenetics

  2022cites this paper
• Inhibition of 14-3-3ε by K50 acetylation activates YAP1 to promote cholangiocarcinoma growth.

  2022cites this paper
• The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification

  2022cites this paper
• The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells

  2022cites this paper
• Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair

  2021cites this paper
• HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

  2021cites this paper
• HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity

  2021cites this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cites this paper
• The Role of Post-Translational Acetylation and Deacetylation of Signaling Proteins and Transcription Factors after Cerebral Ischemia: Facts and Hypotheses

  2021cites this paper
• Mutual Prodrugs of 5‐Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs

  2021cites this paper
• Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

  2021cites this paper
• Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.

  2021cites this paper
• Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells

  2021cites this paper
• Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.

  2021cites this paper
• Hidden pharmacological activities of valproic acid: A new insight.

  2021cites this paper
• A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling.

  2021cites this paper
• Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

  2020cites this paper
• Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma

  2020cites this paper
• Zinc dependent Histone deacetylase inhibitors in cancer therapeutics: Recent update.

  2020cites this paper
• Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance.

  2020cites this paper
• Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.

  2020cites this paper
• ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest

  2020cites this paper
• An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation

  2020cites this paper
• MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.

  2020cites this paper
• Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.

  2020cites this paper
• Las propiedades epigenéticas y anticáncer del ácido valproico

  2020cites this paper
• Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy

  2019cites this paper
• Structurally Diverse Histone Deacetylase Photoreactive Probes: Design, Synthesis, and Photolabeling Studies in Live Cells and Tissue

  2019cites this paper
• Drug Effect Prediction by Integrating L1000 Genomic and Proteomic Big Data.

  2019cites this paper
• Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.

  2019cites this paper
• Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors

  2019cites this paper
• Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure

  2019cites this paper
• Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development

  2019cites this paper
• Up-regulation of TIF1γ by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway.

  2019cites this paper
• Regulation of HDACi−Triggered Autophagy by the Tumor Suppressor Protein p53

  2019cites this paper
• Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma

  2019cites this paper
• Novel 4-(3-phenylpropionamido), 4-(2-phenoxyacetamido) and 4-(cinnamamido) substituted benzamides bearing the pyrazole or indazole nucleus: synthesis, biological evaluation and mechanism of action.

  2019cites this paper
• Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer

  2019cites this paper
• UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress‐mediated apoptosis

  2019cites this paper
• Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy

  2019influential citation
• Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management

  2019cites this paper
• Ovarian solid tumors: Current treatment and recent developments using stimuli-responsive polymers: A systemic review

  2019cites this paper
• An electrochemical study on the redox chemistry of cyclic benzimidazole derivatives with potent anticancer activity

  2019cites this paper
• p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

  2019cites this paper
• Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

  2019cites this paper
• Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasis

  2019cites this paper
• Chemical screen for epigenetic barriers to single allele activation of Oct4

  2019cites this paper
• Nerve-mediated expression of histone deacetylases regulates limb regeneration in axolotls.

  2019cites this paper
• Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy

  2018cites this paper
• Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal

  2018cites this paper
• Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53

  2018cites this paper
• Role of Apoptosis and Mitochondrial Dysfunction in the Treatment of Leukemia Types

  2018cites this paper
• The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone

  2018cites this paper
• Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations

  2018cites this paper
• Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A.

  2018cites this paper
• Histone deacetylases as targets for antitrypanosomal drugs

  2018cites this paper
• N-(2′-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells

  2018cites this paper
• The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer

  2017cites this paper
• Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs

  2017cites this paper
• Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation

  2017cites this paper
• Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar‐to‐ductal metaplasia

  2017cites this paper
• Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

  2017cites this paper
• Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management

  2017cites this paper
• Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches

  2017cites this paper
• Stressing the (Epi)Genome: Dealing with Reactive Oxygen Species in Cancer

  2017cites this paper
• Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

  2017cites this paper
• The discovery and development of romidepsin for the treatment of T-cell lymphoma

  2017cites this paper
• Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

  2017cites this paper
• Combination Therapies Targeting HDAC and IKK in Solid Tumors.

  2017cites this paper
• Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review

  2017cites this paper
• Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro

  2017cites this paper
• Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression

  2017cites this paper
• Chromatin Regulates Genome Targeting with Cisplatin

  2017cites this paper
• Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.

  2017cites this paper
• miR-194-5p/BCLAF1 deregulation in AML tumorigenesis

  2017cites this paper
• Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer

  2017cites this paper
• Histone Deacetylase Inhibitors as Anticancer Drugs

  2017influential citation